Literature DB >> 18709308

Clinical follow-up of 102 anti-Ro/SSA-positive patients with dermatological manifestations.

Karin Popovic1, Marie Wahren-Herlenius, Filippa Nyberg.   

Abstract

Patients with Ro/SSA autoantibodies can develop cutaneous lupus erythematosus and photosensitivity. The aim of this study was to evaluate disease progression and clinical outcome in Ro/SSA-positive patients after 2 years in a prospectively followed cohort. A total of 102 previously clinically and serologically characterized Ro/SSA-positive patients received a questionnaire 2 years after the baseline investigation. Evaluation of 98 questionnaire responses was performed and clinical examination was offered to patients with cutaneous lupus erythematosus established at baseline, or skin symptoms developed over the 2 year period since baseline. Skin symptoms (42%) and arthralgia (31%) were common self-reported health-related answers. Twenty of the 98 patients (20%) showed disease progression with development of new diagnoses such as drug-induced subacute cutaneous lupus erythematosus. This prospective study reveals that new autoimmune diseases and skin disease progress are common in Ro/SSA-positive patients also in the short-term perspective, and stresses the importance of regular follow-up of these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18709308     DOI: 10.2340/00015555-0473

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  8 in total

1.  Ductal epithelial expression of Ro52 correlates with inflammation in salivary glands of patients with primary Sjögren's syndrome.

Authors:  L A Aqrawi; M Kvarnström; K A Brokstad; R Jonsson; K Skarstein; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

Review 2.  Rheumatic manifestations of skin disease.

Authors:  Jennie T Clarke; Victoria P Werth
Journal:  Curr Opin Rheumatol       Date:  2010-01       Impact factor: 5.006

3.  Polymorphisms of the ITGAM gene confer higher risk of discoid cutaneous than of systemic lupus erythematosus.

Authors:  Tiina M Järvinen; Anna Hellquist; Sari Koskenmies; Elisabet Einarsdottir; Jaana Panelius; Taina Hasan; Heikki Julkunen; Leonid Padyukov; Marika Kvarnström; Marie Wahren-Herlenius; Filippa Nyberg; Mauro D'Amato; Juha Kere; Ulpu Saarialho-Kere
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

4.  Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE.

Authors:  Timothy B Niewold; Alexander Meves; Julia S Lehman; Karin Popovic-Silwerfeldt; Aliisa Häyry; Therese Söderlund-Matell; Cristine M Charlesworth; Benjamin Madden; Ingrid E Lundberg; Marie Wahren-Herlenius; Elisabet Svenungsson; Vilija Oke
Journal:  Arthritis Res Ther       Date:  2021-04-30       Impact factor: 5.156

5.  Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: A Case Series of 7 Patients and Brief Review of Literature.

Authors:  Sukhjot Kaur; Palvi Singla; Sandeep Kaur; Amit Kansal; Aditi Bansal; Aminder Singh
Journal:  Indian Dermatol Online J       Date:  2022-01-24

6.  Proton pump inhibitor-induced subacute cutaneous lupus erythematosus.

Authors:  L H Sandholdt; R Laurinaviciene; A Bygum
Journal:  Br J Dermatol       Date:  2014-02       Impact factor: 9.302

7.  Serological epitope profile of anti-Ro52-positive patients with systemic autoimmune rheumatic diseases.

Authors:  Maria Infantino; Francesca Meacci; Valentina Grossi; Maurizio Benucci; Gabriella Morozzi; Elio Tonutti; Marilina Tampoia; Antonina Ott; Wolfgang Meyer; Fabiola Atzeni; Piercarlo Sarzi-Puttini; Mariangela Manfredi; Nicola Bizzaro
Journal:  Arthritis Res Ther       Date:  2015-12-17       Impact factor: 5.156

8.  Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Kaibo Yang; Yanqiu Chen; Hanzhou Qi; Yiling Ye; Zhiping Fan; Fen Huang; Haiyan Zhang; Yuan Suo; Qifa Liu; Hua Jin
Journal:  Front Immunol       Date:  2020-07-28       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.